12/12/2024 - General information
The SAGITTARIUS clinical trial has officially begun with the inclusion of the first six patients in the project. Among them, the first at the Hospital del Mar, a collaborating center in the study, which is coordinated in Spain by Dr. Clara Montagut, head of the Gastrointestinal Tumors section of the Medical Oncology Service and coordinator of the Colorectal Cancer Precision Medicine Research Group at the Hospital del Mar Research Institute.
Més informació "The SAGITTARIUS clinical trial, led by the Hospital del Mar in Spain, gets underway"
11/12/2024 - Press release
Consuming 20-30% of daily energy intake in the morning influences key cardiovascular risk factors. People who consume the right amount of energy in the morning have 2-3.5% lower body mass index, less abdominal obesity (2-4% smaller waist circumference), 9-18% lower triglycerides, and 4-8.5% higher HDL cholesterol (the good cholesterol). Additionally, having a high-quality breakfast with a balanced intake of proteins, high-value fats, fiber, calcium, and iron is associated with a 1.5% smaller waist circumference, 4% lower triglycerides, and 3% higher HDL cholesterol. The study tracked nearly 400 participants of the PREDIMED-Plus study over three years, which analyzes the effects of the Mediterranean diet on participants' health.
Més informació "Having a good breakfast reduces cardiovascular risk"
04/12/2024 - General information
She will hold the position for two years and will be responsible for reviewing and supervising the evaluation processes of each call within her field at the agency. Dr. Esther Barreiro, an associate physician in the Pulmonology Service at Hospital del Mar and a researcher at its research institute, has been appointed as the coordinator in the field of medical and health sciences at the Agency for the Management of University and Research Grants (AGAUR).
02/12/2024 - Press release
A study by the Hospital del Mar Research Institute, in collaboration with the University of Vic-Central University of Catalonia (UVic-UCC), published in the Revista Española de Cardiología, validates the effectiveness of this type of initiative. Implementing out-of-hospital care programs reduces the fatality rate of heart attacks by 35% and long-term mortality by 27%.
26/11/2024 - General information
They are included in the list of the 6,636 most cited researchers worldwide, compiled once again this year by the company. Two researchers from the Hospital del Mar Research Institute are once again among the most cited in the world, according to the Highly Cited Researcher ranking recently published by Clarivate Plc, a company specializing in bibliometrics, business intelligence, and market analysis. The researchers are Dr. Jordi Alonso and Dr. Joaquim Bellmunt, who have been recognized for the relevance of their published studies within their respective fields of expertise.
22/11/2024 - General information
This project will study the short- and long-term impact of steroid sulfation, which is involved in various biological processes, during pregnancy and its influence on maternal mental health and the mother-child bond. The project, "Short- and Long-term Effects of Steroid Sulfation During Pregnancy on Brain Plasticity, Maternal Well-being, and the Mother-Child Bond", led by Dr. Òscar Vilarroya, coordinator of the Neuroimaging of Mental Disorders Research Group at the Hospital del Mar Research Institute, will receive funding from La Marató de TV3 and Catalunya Ràdio. It is one of 26 projects related to sexual and reproductive health selected by the Board of Trustees of La Marató Foundation upon the recommendation of the Advisory Commission. Over 100 proposals were submitted in this edition.
20/11/2024 - General information
The project has received one of the recognitions in the Responsible Research and Innovation in Health awards. The award highlights the added value of the project for incorporating public participation in its design. The PENSA study aims to contribute to the research of effective treatments to prevent or delay dementia.
19/11/2024 - Press release
A scientific article by the PASOS consortium, led by the Gasol Foundation and the Hospital del Mar Research Institute, confirms that nearly 60% of children with overweight present abdominal obesity. 56.1% of the population aged 8 to 16 with overweight (based on BMI) has an excess of fat around the waist, a percentage that 20 years ago stood at 40%. Abdominal obesity is associated with visceral fat, a condition defining cardiometabolic risk, which already affects more than 1 million children aged 8 to 16 in Spain. The PASOS study by the Gasol Foundation continues to contribute to scientific evidence and understanding the issue of childhood obesity.
19/11/2024 - General information
Dr. Cristina Farriols, Dr. Clara Montagut, and Dr. Lluís Recasens will receive the Professional Excellence Awards on November 25 in recognition of their careers. The Colegio de Médicos de Barcelona will recognize the careers of three professionals from Hospital del Mar at the upcoming Professional Excellence Awards. The honorees are Dr. Cristina Farriols, Dr. Clara Montagut, and Dr. Lluís Recasens. The award ceremony will take place on November 25 at the Axa Auditorium of Illa Diagonal.
18/11/2024 - Press release
The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by VHIO investigators, CAR T cells targeting p95HER2 have been engineered to secrete the TECH2Me bispecific antibody. Both therapies specifically and independently recognize tumor cells. In addition, the TECH2Me bispecific antibody activates immune cells within the tumor microenvironment. This dual mechanism of action has demonstrated safety and achieved complete and durable antitumor responses in patient-derived models of HER2+ p95HER2-expressing solid tumors. Published in Nature Communications, results of this VHIO-led study have provided the rationale for the application of a phase 1 first-in-human clinical trial, currently in the approval process, to assess this novel therapeutic strategy in patients with HER2-driven solid tumors.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
